Journal
CANCER LETTERS
Volume 538, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2022.215709
Keywords
Risk factors; Genetic variants; Mitochondrial DNA; Active surveillance; Precision prevention and treatment
Categories
Funding
- National Institute of Health (NIH) [CA233176, CA183929, CA265768, CA173481]
- Prostate Cancer Foundation [21YOUN32]
Ask authors/readers for more resources
Most prostate cancer cases are low-grade tumors that are monitored instead of immediately treated. However, a subset of men are likely to develop advanced prostate cancer, which could be fatal, and they would benefit from early intervention. In this review, the importance of precision intervention is discussed, focusing on the cumulative risk factors for developing or progressing to lethal prostate cancer in high-risk groups.
The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored by active sur-veillance rather than undergoing immediate treatment. However, a subset of men will progress to advanced prostate cancer which may result in lethality, and these men are likely to benefit from early intervention to prevent or delay such progression. For this high-risk group, which includes aged men, men of African descent, and those with a hereditary predisposition to prostate cancer, informed risk stratification can be the cornerstone of clinical decision making and treatment intervention. In this review, we discuss the importance of a precision intervention approach that considers the cumulative risk for a given patient or population to develop prostate cancer or to progress to lethal disease, with particular focus on the interplay of major determinants of high-risk disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available